Erika Yeh

Erika Yeh

Auto-generated profile, based on publicly available information

Erika Yeh

Biotechnology Program, Berkeley City College, Berkeley, CA, 94704, United States

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2008
Verified
Book Chapter
Closed access
PDF file
MPMaria Rita Passos-Bueno
Maria Rita Passos-Bueno
ASAndrea Sertie
Andrea Sertie
FJFernanda S. Jehee
Fernanda S. Jehee
RFRoberto Fanganiello
Roberto Fanganiello
EYErika Yeh
Erika Yeh
Craniosynostosis is a very heterogeneous group of disorders, in the etiology of which genetics play an important role. Chromosomal alterations are important causative mechanisms of the syndromic forms of craniosynostosis accounting for at least 10% of the cases. Mutations in 7 genes are unequivocally associated with mendelian forms of syndromic craniosynostosis: FGFR1, FGFR2, FGFR3, TWIST1, EFNB1, MSX2 and RAB23. Mutations in 4 other genes, FBN1, POR, TGFBR1 and TGFBR2, are also associated with craniosynostosis, but not causing the major clinical feature of the phenotype or with an apparently low penetrance. The identification of these genes represented a great advance in the dissection of the genetics of craniosynostosis in the last 15 years, and today they explain the etiology of about 30% of the syndromic cases. The paucity in the identification of genes associated with this defect has partly been due to the rarity of familial cases. In contrast, very little is known about the molecular and cellular factors leading to nonsyndromic forms of craniosynostosis. Revealing the molecular pathology of craniosynostosis is also of great value for diagnosis, prognosis and genetic counseling. This chapter will review (1) the chromosomal regions associated with syndromic forms of the malformation, (2) the genes in which a large number of mutations have been reported by independent studies (FGFR1, FGFR2, FGFR3, TWIST1 and EFNB1) and (3) the molecular mechanisms and genotype-phenotype correlations of such mutations.

1 July 2006 in Brazilian Journal of Medical and Biological Research
Verified
Journal Article
Open access
PDF file
FEF.I.V. Errera
F.I.V. Errera
MSM.E.R. Silva
M.E.R. Silva
EYE. Yeh
E. Yeh
CMC.M.C. Maranduba
C.M.C. Maranduba
BFB. Folco
B. Folco
MPMaria Rita Passos-Bueno
Maria Rita Passos-Bueno
Diabetes mellitus (DM) is a highly prevalent complex genetic disorder. There has been a worldwide effort in the identification of susceptibility genes for DM and its complications, and the 5-10-methylenetetrahydrofolate reductase (MTHFR) and apolipoprotein-E (APOE) genes have been considered good candidate susceptibility genes to this condition. The objectives of the present study were to determine if the 677T MTHFR and epsilon2/epsilon3/epsilon4 APOE alleles are risk factors for DM and for severity of diabetic retinopathy (DR). A total of 248 individuals were studied: 107 healthy individuals and 141 diabetic patients (46 with type 1 diabetes and 95 with type 2 diabetes), who also had DR (81 with non-proliferative DR and 60 with proliferative DR). The polymorphisms were analyzed by PCR followed by digestion with restriction enzyme or the single-nucleotide primer extension method. No evidence of association between the 677TT genotype of MTHFR gene and DM [cases: TT = 10/95 (10.6%); controls: TT = 14/107 (13%)] or with severity of DR was observed [cases: TT = 5/60 (8.5%); controls: TT = 9/81 (11.1%); P > 0.05]. We also did not find evidence of an association between APOE alleles and proliferative DR (epsilon2, epsilon3 and epsilon4 in cases: 9, 76, and 15%, and in controls: 5, 88, and 12%, respectively) but the carriers of epsilon2 allele were more frequent among patients with type 2 DM and DR than in controls [cases: 15/95 (15.8%); controls: 7/107 (6.5%); P < 0.05]. Therefore, our results suggest that the epsilon2 allele/APOE might be a risk factor for diabetes in the Brazilian population.

10 November 2010 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JBJoseph R. Bishop
Joseph R. Bishop
MPMaria Rita Passos-Bueno
Maria Rita Passos-Bueno
LFLoren Fong
Loren Fong
KSKristin I. Stanford
Kristin I. Stanford
JGJon C. Gonzales
Jon C. Gonzales
KMKaren Moulton
Karen Moulton
Lipoprotein lipase (Lpl) acts on triglyceride-rich lipoproteins in the peripheral circulation, liberating free fatty acids for energy metabolism or storage. This essential enzyme is synthesized in parenchymal cells of adipose tissue, heart, and skeletal muscle and migrates to the luminal side of the vascular endothelium where it acts upon circulating lipoproteins. Prior studies suggested that Lpl is immobilized by way of heparan sulfate proteoglycans on the endothelium, but genetically altering endothelial cell heparan sulfate had no effect on Lpl localization or lipolysis. The objective of this study was to determine if extracellular matrix proteoglycans affect Lpl distribution and triglyceride metabolism. We examined mutant mice defective in collagen XVIII (Col18), a heparan sulfate proteoglycan present in vascular basement membranes. Loss of Col18 reduces plasma levels of Lpl enzyme and activity, which results in mild fasting hypertriglyceridemia and diet-induced hyperchylomicronemia. Humans with Knobloch Syndrome caused by a null mutation in the vascular form of Col18 also present lower than normal plasma Lpl mass and activity and exhibit fasting hypertriglyceridemia. This is the first report demonstrating that Lpl presentation on the lumenal side of the endothelium depends on a basement membrane proteoglycan and demonstrates a previously unrecognized phenotype in patients lacking Col18.

11 January 2017 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
IMIleena Mitra
Ileena Mitra
ALAlinoë Lavillaureix
Alinoë Lavillaureix
EYErika Yeh
Erika Yeh
MTMichela Traglia
Michela Traglia
KTKathryn Tsang
Kathryn Tsang
LWLauren A. Weiss
Lauren A. Weiss
Although gene-gene interaction, or epistasis, plays a large role in complex traits in model organisms, genome-wide by genome-wide searches for two-way interaction have limited power in human studies. We thus used knowledge of a biological pathway in order to identify a contribution of epistasis to autism spectrum disorders (ASDs) in humans, a reverse-pathway genetic approach. Based on previous observation of increased ASD symptoms in Mendelian disorders of the Ras/MAPK pathway (RASopathies), we showed that common SNPs in RASopathy genes show enrichment for association signal in GWAS (P = 0.02). We then screened genome-wide for interactors with RASopathy gene SNPs and showed strong enrichment in ASD-affected individuals (P < 2.2 x 10−16), with a number of pairwise interactions meeting genome-wide criteria for significance. Finally, we utilized quantitative measures of ASD symptoms in RASopathy-affected individuals to perform modifier mapping via GWAS. One top region overlapped between these independent approaches, and we showed dysregulation of a gene in this region, GPR141, in a RASopathy neural cell line. We thus used orthogonal approaches to provide strong evidence for a contribution of epistasis to ASDs, confirm a role for the Ras/MAPK pathway in idiopathic ASDs, and to identify a convergent candidate gene that may interact with the Ras/MAPK pathway. The contribution of epistasis to human biology and complex trait architecture has been subject to intense debate. Despite statistical methods to detect interaction, allele frequencies and study designs have limited our power to address this question. Rather than a statistically-motivated approach, we developed a reverse pathway genetic approach to detect epistasis in in autism spectrum disorders (ASDs). Instead of traditional pathway analysis—exploiting unbiased genetic results to identify biological pathways important for pathophysiology—we hypothesized that the reverse approach of leveraging a specific biological pathway to uncover novel aspects of genetic architecture could be fruitful. We drew on knowledge from Mendelian disorders of the Ras/MAPK pathway (RASopathies) associated with ASD to inform our analyses. First, we implemented an epistasis screen in idiopathic ASD for SNPs that interact with the Ras/MAPK pathway, allowing us to detect genome-wide enrichment in epistasis signal as well as specific interacting loci. Second, we performed modifier mapping within RASopathies and identified overlapping signals with our first approach. Finally, we took the top overlapping region and experimentally demonstrated dysregulated expression in iPSC-derived neural cells from RASopathy subjects. Together, our results establish a human genetics motivated reverse-pathway strategy, which can be applied broadly to study epistasis.

1 February 2007 in Diabetes Care
Verified
Journal Article
Open access
PDF file
FEFlavia I.V. Errera
Flavia I.V. Errera
LCLuís Henrique Canani
Luís Henrique Canani
MSMaria Elisabeth R. Silva
Maria Elisabeth R. Silva
EYErika Yeh
Erika Yeh
WTWalter Takahashi
Walter Takahashi
MPMaria Rita Passos-Bueno
Maria Rita Passos-Bueno
OBJECTIVE—The purpose of this study was to evaluate the effect of the single nucleotide polymorphism (SNP) −634G>C at the 5′ regulatory region of the vascular endothelial growth factor (VEGF) in the risk of proliferative diabetic retinopathy (PDR) in the Brazilian population of European ancestry with type 2 diabetes. RESEARCH DESIGN AND METHODS—A case-control study was conducted in 501 type 2 diabetic patients of European ancestry. Patients underwent a standardized clinical, ophthalmological, and laboratory evaluation. Of these, 167 patients had PDR (case patients), and 334 were considered as control subjects (patients without PDR) for PDR. A reference population (110 individuals of European ancestry) was also evaluated. RESULTS—No evidence of association between −634G>C/VEGF and the presence of diabetic retinopathy or type 2 diabetes was observed (P > 0.05). However, CC homozygous for the SNP −634G>C was significantly more frequent in patients with PDR (37 of 167; 22.2%) than in the corresponding control group (40 of 334; 12%) in accordance with a recessive model (P = 0.003). This effect was further observed when creatinine, BMI, sex, duration of type 2 diabetes, HDL cholesterol, and systolic blood pressure were taken into account (odds ratio 1.9 [95% CI 1.01–3.79], P = 0.04). CONCLUSIONS—The presence of the allele −634C/VEGF in homozygosity is an independent risk factor for the development of PDR in type 2 diabetic patients of European ancestry.

6 January 2016 in Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
GRGemma E. Rooney
Gemma E. Rooney
AGAlice F. Goodwin
Alice F. Goodwin
PDPhilippe Depeille
Philippe Depeille
ASAmnon Sharir
Amnon Sharir
CSClaude M. Schofield
Claude M. Schofield
EUErik M. Ullian
Erik M. Ullian
Increasing evidence implicates abnormal Ras signaling as a major contributor in neurodevelopmental disorders, yet how such signaling causes cortical pathogenesis is unknown. We examined the consequences of aberrant Ras signaling in the developing mouse brain and uncovered several critical phenotypes, including increased production of cortical neurons and morphological deficits. To determine whether these phenotypes are recapitulated in humans, we generated induced pluripotent stem (iPS) cell lines from patients with Costello syndrome (CS), a developmental disorder caused by abnormal Ras signaling and characterized by neurodevelopmental abnormalities, such as cognitive impairment and autism. Directed differentiation toward a neuroectodermal fate revealed an extended progenitor phase and subsequent increased production of cortical neurons. Morphological analysis of mature neurons revealed significantly altered neurite length and soma size in CS patients. This study demonstrates the synergy between mouse and human models and validates the use of iPS cells as a platform to study the underlying cellular pathologies resulting from signaling deficits.SIGNIFICANCE STATEMENTIncreasing evidence implicates Ras signaling dysfunction as a major contributor in psychiatric and neurodevelopmental disorders, such as cognitive impairment and autism, but the underlying cortical cellular pathogenesis remains unclear. This study is the first to reveal human neuronal pathogenesis resulting from abnormal Ras signaling and provides insights into how these phenotypic abnormalities likely contribute to neurodevelopmental disorders. We also demonstrate the synergy between mouse and human models, thereby validating the use of iPS cells as a platform to study underlying cellular pathologies resulting from signaling deficits. Recapitulating human cellular pathologiesin vitrofacilitates the future high throughput screening of potential therapeutic agents that may reverse phenotypic and behavioral deficits.